FDA Inspection 1021136 — BioSpectra, Inc.
The FDA completed an inspection of BioSpectra, Inc. on August 1, 2017 in Bangor, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- August 1, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Bangor, PA (United States)